Plain-English translation of NCT06372587 on ClinicalTrials.gov ↗ ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a basic science study testing a new approach to Alzheimer's disease using genetically encoded engineered proteins (GEEPs) that researchers developed in the lab. Instead of using antibodies like most Alzheimer's treatments, these engineered proteins are designed to strengthen the connections between brain cells and restore the brain's ability to form memories and learn. Researchers will grow human brain cells from skin samples taken from Alzheimer's patients and healthy volunteers, then test how well the medication works in these cells.
Most Alzheimer's drugs have failed because the disease is complex and affects the brain in multiple ways. This trial exists to test a completely different approach — one that targets the core problem of how brain cells communicate and change in response to experience, rather than just targeting protein buildup.
You likely qualify if…
You likely don't qualify if…
You would have a small skin biopsy taken (a 4 mm sample using local anesthesia, similar to a punch biopsy). Skin cells from your biopsy would then be reprogrammed into brain cells in the laboratory, where researchers would test the engineered proteins. This is not a treatment study — the work happens in the lab, not in your body. The entire study involves this single skin biopsy visit.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Italy